Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 12/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 12/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 10/20 | 0.46 |
| ▸ | CHRNB1 | P11230 | 9/20 | 0.46 |
| ▸ | CHRNB3 | Q05901 | 9/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4266574 | 0.99 | CHRNB4 (0.45) | CHRNB4CHRNA3CHRNB2CHRNB1CHRNB3 | |
| SCHEMBL4090020 | 0.89 | LRRK2 (0.42) | — | |
| SCHEMBL4083912 | 0.87 | CHRNB2 (0.48) | CHRNB4CHRNA3CHRNB2CHRNB1CHRNB3 | |
| SCHEMBL4083908 | 0.87 | CHRNB2 (0.48) | CHRNB4CHRNA3CHRNB2CHRNB1CHRNB3 | |
| SCHEMBL4171537 | 0.86 | TTK (0.50) | CHRNB4CHRNA3CHRNB2CHRNB1CHRNB3 | |
| SCHEMBL4171533 | 0.86 | TTK (0.50) | CHRNB4CHRNA3CHRNB2CHRNB1CHRNB3 | |
| SCHEMBL4178646 | 0.85 | TTK (0.40) | — | |
| SCHEMBL4039462 | 0.83 | CLK2 (0.51) | — | |
| SCHEMBL4084704 | 0.82 | CLK2 (0.53) | — | |
| SCHEMBL4089635 | 0.82 | CLK2 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2065383-A1 | Indazole compounds and methods of use thereof as protein kinase inhibitors | Signal Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
| EP-1692128-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | Signal Pharmaceuticals LLC (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | BHAGWAT SHRIPAD S | 2006-01-05 | — | — | US | disclosed |
| WO-2005051942-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WNT3, WNT3A, WNK3 | CHRNB4 3071/4885CHRNA3 1612/4885CHRNB2 3046/4885 |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | WNT3, WNT3A, WNK3 | CHRNB4 3275/4885CHRNA3 1808/4885CHRNB2 3229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.